NL301004I2 - Dacomitinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout - Google Patents

Dacomitinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout

Info

Publication number: NL301004I2
Authority: NL; Netherlands
Prior art keywords: dacomitinib; optionally; pharmaceutically acceptable; acceptable salt; salt
Prior art date: 2004-05-06

Application number

NL301004C

Other languages

English (en)

Original Assignee

Warner Lambert Company Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-05-06

Filing date

2019-09-05

Publication date

2026-01-21

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34965519&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL301004(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2019-09-05 Application filed by Warner Lambert Company Llc filed Critical Warner Lambert Company Llc

2026-01-21 Publication of NL301004I2 publication Critical patent/NL301004I2/nl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Immunology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Oncology (AREA)
Endocrinology (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Cardiology (AREA)
Diabetes (AREA)
Transplantation (AREA)
Obesity (AREA)
Pulmonology (AREA)
Vascular Medicine (AREA)
Ophthalmology & Optometry (AREA)
Dermatology (AREA)
Gastroenterology & Hepatology (AREA)
Reproductive Health (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

NL301004C 2004-05-06 2019-09-05 Dacomitinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout NL301004I2 (nl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US56887204P	2004-05-06	2004-05-06
PCT/IB2005/001139 WO2005107758A1 (en)	2004-05-06	2005-04-25	4-phenylamino-quinazolin-6-yl-amides

Publications (1)

Publication Number	Publication Date
NL301004I2 true NL301004I2 (nl)	2026-01-21

Family

ID=34965519

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NL1028967A NL1028967C2 (nl)	2004-05-06	2005-05-04	4-Fenylamino-chinazoline-6-yl-amiden.
NL301004C NL301004I2 (nl)	2004-05-06	2019-09-05	Dacomitinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
NL1028967A NL1028967C2 (nl)	2004-05-06	2005-05-04	4-Fenylamino-chinazoline-6-yl-amiden.

Country Status (47)

Country	Link
US (3)	US7772243B2 (nl)
EP (1)	EP1746999B1 (nl)
JP (2)	JP4205757B2 (nl)
KR (2)	KR20080095915A (nl)
CN (1)	CN1972688B (nl)
AP (1)	AP2204A (nl)
AR (1)	AR048652A1 (nl)
AT (1)	ATE533490T1 (nl)
AU (1)	AU2005239878B9 (nl)
BE (1)	BE2019C540I2 (nl)
BR (1)	BRPI0510604B8 (nl)
CA (1)	CA2565812C (nl)
CR (1)	CR8727A (nl)
CY (2)	CY1112127T1 (nl)
DK (1)	DK1746999T3 (nl)
EA (1)	EA011237B1 (nl)
EC (1)	ECSP066976A (nl)
ES (1)	ES2374553T3 (nl)
FR (1)	FR19C1052I2 (nl)
GE (1)	GEP20084551B (nl)
GT (1)	GT200500103A (nl)
HN (1)	HN2005000192A (nl)
HR (1)	HRP20110958T1 (nl)
HU (1)	HUS1900039I1 (nl)
IL (1)	IL178822A (nl)
LT (1)	LTC1746999I2 (nl)
LU (1)	LUC00127I2 (nl)
MA (1)	MA28632B1 (nl)
ME (1)	ME01267B (nl)
MX (1)	MXPA06012756A (nl)
MY (1)	MY143566A (nl)
NI (1)	NI200600262A (nl)
NL (2)	NL1028967C2 (nl)
NO (2)	NO339692B1 (nl)
NZ (1)	NZ550796A (nl)
PA (1)	PA8631901A1 (nl)
PE (1)	PE20060215A1 (nl)
PL (1)	PL1746999T3 (nl)
PT (1)	PT1746999E (nl)
RS (1)	RS52119B (nl)
SI (1)	SI1746999T1 (nl)
TN (1)	TNSN06360A1 (nl)
TW (1)	TWI334865B (nl)
UA (1)	UA85706C2 (nl)
UY (1)	UY28885A1 (nl)
WO (1)	WO2005107758A1 (nl)
ZA (1)	ZA200609012B (nl)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2005107758A1 (en) *	2004-05-06	2005-11-17	Warner-Lambert Company Llc	4-phenylamino-quinazolin-6-yl-amides
KR100735639B1 (ko)	2004-12-29	2007-07-04	한미약품 주식회사	암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법
KR100929146B1 (ko)	2006-06-28	2009-12-01	한미약품 주식회사	암세포 성장 억제 효과를 갖는 퀴나졸린 유도체
WO2010104406A1 (en)	2009-03-11	2010-09-16	Auckland Uniservices Limited	Prodrug forms of kinase inhibitors and their use in therapy
CN102146059A (zh) *	2010-02-08	2011-08-10	上海艾力斯医药科技有限公司	喹唑啉衍生物、制备方法及其应用
CN102382106A (zh)	2010-08-30	2012-03-21	黄振华	苯胺取代的喹唑啉衍生物
CN102382065B (zh) *	2010-08-30	2014-05-28	山东轩竹医药科技有限公司	苯胺取代的喹唑啉衍生物
CN102452989B (zh) *	2010-10-19	2014-10-22	山东轩竹医药科技有限公司	苯胺取代的喹唑啉衍生物
US8828391B2 (en)	2011-05-17	2014-09-09	Boehringer Ingelheim International Gmbh	Method for EGFR directed combination treatment of non-small cell lung cancer
DK2716633T3 (en)	2011-05-26	2017-07-17	Xuanzhu Pharma Co Ltd	QUINAZOLINE DERIVATIVE AS A TYROSIN-KINASE INHIBITOR, PROCEDURE FOR PREPARING IT AND USING THEREOF
CN102838590B (zh) *	2011-06-21	2014-07-09	苏州迈泰生物技术有限公司	氨基喹唑啉衍生物及其在制备抗恶性肿瘤药物中的用途
EP2766356B1 (en) *	2011-10-12	2018-08-01	Teligene Ltd.	Quinazoline derivatives as kinases inhibitors and methods of use thereof
RS55704B1 (sr)	2012-01-17	2017-07-31	Astellas Pharma Inc	Jedinjenje pirazin karboksamida
JP2015515995A (ja)	2012-05-07	2015-06-04	テリジェンリミテッドＴｅｌｉｇｅｎｅＬｔｄ	キナーゼ阻害剤として有用な置換アミノキナゾリン
CN104119350B (zh)	2013-04-28	2017-04-12	广东东阳光药业有限公司	氨基喹唑啉类衍生物及其盐和使用方法
CN103288758B (zh) *	2013-05-16	2015-01-21	苏州明锐医药科技有限公司	一种达克米替尼的制备方法
CN103288759B (zh) *	2013-05-16	2015-05-20	苏州明锐医药科技有限公司	达克米替尼的制备方法
US9694011B2 (en)	2013-05-21	2017-07-04	Jiangsu Medolution Ltd	Substituted pyrazolopyrimidines as kinases inhibitors
CN103304492B (zh) *	2013-06-20	2015-12-23	湖南欧亚生物有限公司	一种EGFR抑制剂Dacomitinib的合成方法
US9714235B2 (en) *	2013-07-18	2017-07-25	Shanghai Fochon Pharmaceutical Co., Ltd.	Quinazoline derivatives, compositions thereof, and use as pharmaceuticals
CN105859641B (zh) *	2015-05-05	2018-11-16	杭州华东医药集团新药研究院有限公司	喹唑啉巴豆基化合物二马来酸盐的晶体及其制备方法和用途
AU2017204973A1 (en) *	2016-01-06	2018-07-12	Trillium Therapeutics Inc.	Novel fluorinated quinazoline derivatives as EGFR inhibitors
CN107721987A (zh) *	2016-08-12	2018-02-23	山东轩竹医药科技有限公司	喹唑啉类酪氨酸激酶抑制剂的晶型
CN107721985A (zh) *	2016-08-12	2018-02-23	山东轩竹医药科技有限公司	喹唑啉类酪氨酸激酶抑制剂的晶型
CN107721986A (zh) *	2016-08-12	2018-02-23	山东轩竹医药科技有限公司	喹唑啉类酪氨酸激酶抑制剂的晶型
CN107793368B (zh) *	2016-08-31	2021-10-15	四川科伦药物研究院有限公司	达可替尼溶剂化物、其新晶型及其制备方法和用途
KR102213040B1 (ko) *	2017-12-20	2021-02-05	한국원자력의학원	방사선 손상 보호 또는 완화, 및 폐섬유화 예방 또는 치료 용도
CN109438423A (zh) *	2018-09-12	2019-03-08	通化师范学院	一种肺癌靶向化合物azd-3759的合成工艺的新方法
WO2020068867A1 (en)	2018-09-25	2020-04-02	Black Diamond Therapeutics, Inc.	Quinazoline derivatives as tyrosine kinase inhibitor, compositions, methods of making them and their use
US20220040324A1 (en)	2018-12-21	2022-02-10	Daiichi Sankyo Company, Limited	Combination of antibody-drug conjugate and kinase inhibitor
US12465608B2 (en)	2019-03-29	2025-11-11	Astrazeneca Ab	Osimertinib for use in the treatment of non-small cell lung cancer
CN114787150A (zh)	2019-08-15	2022-07-22	黑钻治疗公司	炔基喹唑啉化合物
US20210161897A1 (en)	2019-11-12	2021-06-03	Astrazeneca Ab	Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
CN113045541A (zh) *	2019-12-27	2021-06-29	广东东阳光药业有限公司	Egfr抑制剂新晶型及其制备方法
AU2021211871A1 (en)	2020-01-20	2022-09-08	Astrazeneca Ab	Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
CN113717111A (zh) *	2020-05-25	2021-11-30	苏州晶云药物科技股份有限公司	喹唑啉类化合物的晶型及其制备方法
US20210369709A1 (en)	2020-05-27	2021-12-02	Astrazeneca Ab	EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
JP7758369B2 (ja)	2020-07-10	2025-10-22	ザリージェンツオブザユニバーシティオブミシガン	Ｇａｓ４１阻害剤及びその使用方法
CN112707869B (zh) *	2020-12-25	2022-03-22	扬子江药业集团有限公司	一种达可替尼杂质及其制备方法
AU2023246862A1 (en)	2022-03-31	2024-10-31	Astrazeneca Ab	Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer
WO2023209090A1 (en)	2022-04-28	2023-11-02	Astrazeneca Ab	Bicyclic heteroaromatic compounds and their application in the treatment of cancer
WO2023209086A1 (en)	2022-04-28	2023-11-02	Astrazeneca Ab	Bicyclic heteroaromatic compounds for treating cancer
WO2023209088A1 (en)	2022-04-28	2023-11-02	Astrazeneca Ab	Bicyclic heteroaromatic compounds and their use in the treatment of cancer
JP2025516171A (ja)	2022-04-28	2025-05-27	アストラゼネカ・アクチエボラーグ	縮合二環式ヘテロ芳香族化合物及び癌の治療におけるその使用
CA3259492A1 (en)	2022-06-27	2024-01-04	Astrazeneca Ab	COMBINATIONS INVOLVING EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1340821C (en)	1988-10-06	1999-11-16	Nobuyuki Fukazawa	Heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components
MX22406A (es)	1989-09-15	1994-01-31	Pfizer	Nuevos derivados de n-aril y n-heteroarilamidas y urea como inhibidores de acil coenzima a: acil transferasa del colesterol (acat).
US5362878A (en)	1991-03-21	1994-11-08	Pfizer Inc.	Intermediates for making N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase (ACAT)
AU665207B2 (en)	1991-07-29	1995-12-21	Warner-Lambert Company	Quinazoline derivatives as acetylcholinesterase inhibitors
US5366987A (en)	1991-08-22	1994-11-22	Warner-Lambert Company	Isoxazolyl-substituted alkyl amide ACAT inhibitors
RU2117664C1 (ru)	1991-08-22	1998-08-20	Варнер-Ламберт Компани	Производные тетразолсодержащего амида, смесь их изомеров, отдельные изомеры или фармацевтически приемлемые соли
GB9300059D0 (en)	1992-01-20	1993-03-03	Zeneca Ltd	Quinazoline derivatives
US5412714A (en) *	1992-02-24	1995-05-02	At&T Corp.	Mnemonic and synonymic addressing in a telecommunications system
GB9323290D0 (en)	1992-12-10	1994-01-05	Zeneca Ltd	Quinazoline derivatives
PH31122A (en)	1993-03-31	1998-02-23	Eisai Co Ltd	Nitrogen-containing fused-heterocycle compounds.
GB9314893D0 (en)	1993-07-19	1993-09-01	Zeneca Ltd	Quinazoline derivatives
US5736534A (en)	1994-02-23	1998-04-07	Pfizer Inc.	4-heterocyclyl-substituted quinazoline derivatives, processes for their preparation and their use as anti-cancer agents
GB9510757D0 (en)	1994-09-19	1995-07-19	Wellcome Found	Therapeuticaly active compounds
TW321649B (nl)	1994-11-12	1997-12-01	Zeneca Ltd
GB9424233D0 (en)	1994-11-30	1995-01-18	Zeneca Ltd	Quinazoline derivatives
GB9508565D0 (en)	1995-04-27	1995-06-14	Zeneca Ltd	Quiazoline derivative
GB9508538D0 (en) *	1995-04-27	1995-06-14	Zeneca Ltd	Quinazoline derivatives
WO1996033977A1 (en)	1995-04-27	1996-10-31	Zeneca Limited	Quinazoline derivatives
GB9508537D0 (en)	1995-04-27	1995-06-14	Zeneca Ltd	Quinazoline derivatives
US5747498A (en)	1996-05-28	1998-05-05	Pfizer Inc.	Alkynyl and azido-substituted 4-anilinoquinazolines
GB9514265D0 (en)	1995-07-13	1995-09-13	Wellcome Found	Hetrocyclic compounds
US6008230A (en)	1995-10-16	1999-12-28	Fujisawa Pharmaceutical Co., Ltd.	Quinoline compounds as H+ -ATPases
GB9624482D0 (en)	1995-12-18	1997-01-15	Zeneca Phaema S A	Chemical compounds
US5760041A (en)	1996-02-05	1998-06-02	American Cyanamid Company	4-aminoquinazoline EGFR Inhibitors
JP4471404B2 (ja)	1996-02-13	2010-06-02	アストラゼネカユーケイリミテッド	Ｖｅｇｆインヒビターとしてのキナゾリン誘導体
GB9603097D0 (en)	1996-02-14	1996-04-10	Zeneca Ltd	Quinazoline compounds
GB9603095D0 (en)	1996-02-14	1996-04-10	Zeneca Ltd	Quinazoline derivatives
KR100489174B1 (ko)	1996-03-05	2005-09-30	제네카-파마 소시에떼아노님	4-아닐리노퀴나졸린유도체
GEP20012442B (en) *	1996-04-12	2001-05-25	Warner Lambert Co	Irreversible Inhibitors of Tyrosine Kinases
GB9607729D0 (en)	1996-04-13	1996-06-19	Zeneca Ltd	Quinazoline derivatives
EP0912559B1 (en)	1996-07-13	2002-11-06	Glaxo Group Limited	Fused heterocyclic compounds as protein tyrosine kinase inhibitors
HRP970371A2 (en)	1996-07-13	1998-08-31	Kathryn Jane Smith	Heterocyclic compounds
GB9718972D0 (en)	1996-09-25	1997-11-12	Zeneca Ltd	Chemical compounds
US6225318B1 (en)	1996-10-17	2001-05-01	Pfizer Inc	4-aminoquinazolone derivatives
WO1998038984A2 (en)	1997-03-05	1998-09-11	Sugen, Inc.	Formulations for hydrophobic pharmaceutical agents
UA73073C2 (uk)	1997-04-03	2005-06-15	Уайт Холдінгз Корпорейшн	Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6002008A (en)	1997-04-03	1999-12-14	American Cyanamid Company	Substituted 3-cyano quinolines
AR012634A1 (es)	1997-05-02	2000-11-08	Sugen Inc	Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
AU7165698A (en)	1997-05-06	1998-11-27	American Cyanamid Company	Use of quinazoline compounds for the treatment of polycystic kidney disease
US5929080A (en)	1997-05-06	1999-07-27	American Cyanamid Company	Method of treating polycystic kidney disease
ZA986729B (en)	1997-07-29	1999-02-02	Warner Lambert Co	Irreversible inhibitors of tyrosine kinases
ZA986732B (en)	1997-07-29	1999-02-02	Warner Lambert Co	Irreversible inhibitiors of tyrosine kinases
US6251912B1 (en)	1997-08-01	2001-06-26	American Cyanamid Company	Substituted quinazoline derivatives
TW436485B (en)	1997-08-01	2001-05-28	American Cyanamid Co	Substituted quinazoline derivatives
AU1308799A (en)	1997-11-06	1999-05-31	American Cyanamid Company	Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps
US6323209B1 (en)	1997-11-06	2001-11-27	American Cyanamid Company	Method of treating or inhibiting colonic polyps
GB9800569D0 (en)	1998-01-12	1998-03-11	Glaxo Group Ltd	Heterocyclic compounds
GB9800575D0 (en)	1998-01-12	1998-03-11	Glaxo Group Ltd	Heterocyclic compounds
KR20010052450A (ko)	1998-05-28	2001-06-25	파커 휴우즈 인스티튜트	뇌종양 치료를 위한 퀴나졸린
US6384223B1 (en)	1998-07-30	2002-05-07	American Home Products Corporation	Substituted quinazoline derivatives
BR9912575A (pt)	1998-07-30	2001-05-02	American Home Prod	Processo para a preparação de um composto, e, composto.
US6297258B1 (en)	1998-09-29	2001-10-02	American Cyanamid Company	Substituted 3-cyanoquinolines
JP4537582B2 (ja)	1998-09-29	2010-09-01	アメリカン・サイアナミド・カンパニー	プロテインチロシンキナーゼインヒビターとしての置換３−シアノキノリン
EA003786B1 (ru)	1998-11-19	2003-10-30	Варнер Ламберт Компани	N-[4-(3-хлор-4-фторфениламино)-7-(3-морфолин-4-илпропокси)хиназолин-6-ил]акриламид - необратимый ингибитор тирозинкиназ
EE200100449A (et)	1999-02-27	2002-12-16	Boehringer Ingelheim Pharma Kg	4-aminokinasoliini ja kinoliini derivaadid inhibeeriva toimega türosiinkinaaside vahendatud signaali ülekandele
DE19911509A1 (de)	1999-03-15	2000-09-21	Boehringer Ingelheim Pharma	Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
RS49836B (sr)	1999-03-31	2008-08-07	Pfizer Products Inc.,	Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja
IL147133A0 (en) *	1999-06-21	2002-08-14	Boehringer Ingelheim Pharma	Bicyclic heterocycles, medicaments containing these compounds, their use and methods for the production thereof
AUPQ113799A0 (en) *	1999-06-22	1999-07-15	University Of Queensland, The	A method and device for measuring lymphoedema
CN1229142C (zh)	1999-08-12	2005-11-30	惠氏控股有限公司	用于治疗或抑制结肠息肉和结肠直肠癌的含有nsaid和efgr激酶抑制剂的组合物
US7081461B1 (en)	1999-09-21	2006-07-25	Astrazeneca Ab	Quinazoline compounds and pharmaceutical compositions containing them
US6664390B2 (en)	2000-02-02	2003-12-16	Warner-Lambert Company Llc	Method for the simplified production of (3-chloro-4-fluorophenyl)-[7-(3-morpholin-4-yl-propoxy)-6-nitro-quinazoline-4-yl]-amine or (3-chloro-4-fluorophenyl)-[7-(3-morpholin-4-yl-propoxy)-6-amino-quinazoline-4-yl]-amine
US6384051B1 (en)	2000-03-13	2002-05-07	American Cyanamid Company	Method of treating or inhibiting colonic polyps
PT1274692E (pt)	2000-04-07	2006-11-30	Astrazeneca Ab	Compostos de quinazolina
US6627634B2 (en)	2000-04-08	2003-09-30	Boehringer Ingelheim Pharma Kg	Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them
AU6383101A (en) *	2000-04-08	2001-10-23	Boehringer Ingelheim Pharma Kg	Bicyclic heterocylces, medicaments containing said compounds, the use thereof and method for producing them
UA73993C2 (uk)	2000-06-06	2005-10-17	Астразенека Аб	Хіназолінові похідні для лікування пухлин та фармацевтична композиція
DE10031971A1 (de)	2000-06-30	2002-01-10	Goedecke Ag	Polymorphe Formen/Hydrate von N-[4-(3-Chlor-4-fluor-phenylamino)-7-(3-morpholin-4-yl-propoxy)-chinazolin-6-yl]-acrylamid Dihydrochlorid, Verfahren zu ihrer Herstellung sowie die Verwendung derselben zur Herstellung von Medikamenten mit irreversibler Tyrosinkinasehemmwirkung
US6446671B2 (en) *	2000-08-04	2002-09-10	John G. Armenia	Double wall safety hose
US6656946B2 (en)	2000-08-26	2003-12-02	Boehringer Ingelheim Pharma Kg	Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
US6653305B2 (en)	2000-08-26	2003-11-25	Boehringer Ingelheim Pharma Kg	Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them
US6617329B2 (en)	2000-08-26	2003-09-09	Boehringer Ingelheim Pharma Kg	Aminoquinazolines and their use as medicaments
US20020082270A1 (en)	2000-08-26	2002-06-27	Frank Himmelsbach	Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
US6403580B1 (en)	2000-08-26	2002-06-11	Boehringer Ingelheim Pharma Kg	Quinazolines, pharmaceutical compositions containing these compounds, their use and processes for preparing them
US6740651B2 (en)	2000-08-26	2004-05-25	Boehringer Ingelheim Pharma Kg	Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
ATE419239T1 (de)	2000-10-20	2009-01-15	Eisai R&D Man Co Ltd	Verfahren zur herstellung von 4-phenoxy chinolin derivaten
US20030158196A1 (en)	2002-02-16	2003-08-21	Boehringer Ingelheim Pharma Gmbh Co. Kg	Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors
US7019012B2 (en)	2000-12-20	2006-03-28	Boehringer Ingelheim International Pharma Gmbh & Co. Kg	Quinazoline derivatives and pharmaceutical compositions containing them
DE10063435A1 (de) *	2000-12-20	2002-07-04	Boehringer Ingelheim Pharma	Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
PA8539401A1 (es)	2001-02-14	2002-10-28	Warner Lambert Co	Quinazolinas como inhibidores de mmp-13
KR100861486B1 (ko)	2001-02-21	2008-10-02	미쓰비시 타나베 파마 코퍼레이션	퀴나졸린 유도체
WO2002092577A1 (en)	2001-05-14	2002-11-21	Astrazeneca Ab	Quinazoline derivatives
WO2002092578A1 (en)	2001-05-14	2002-11-21	Astrazeneca Ab	Quinazoline derivatives
GB0118752D0 (en)	2001-08-01	2001-09-26	Pfizer Ltd	Process for the production of quinazolines
GB0126433D0 (en)	2001-11-03	2002-01-02	Astrazeneca Ab	Compounds
ATE423104T1 (de)	2001-11-03	2009-03-15	Astrazeneca Ab	Quinazolin derivate als antitumor-mittel
GB0128108D0 (en)	2001-11-23	2002-01-16	Astrazeneca Ab	Therapeutic use
IL160971A0 (en)	2001-11-30	2004-08-31	Pfizer Prod Inc	Processes for the preparation of substituted bicyclic derivatives for the treatment of abnormal cell growth
JP4181502B2 (ja)	2001-12-12	2008-11-19	ファイザー・プロダクツ・インク	異常な細胞増殖を治療するためのキナゾリン誘導体
US7402585B2 (en)	2001-12-24	2008-07-22	Astrazeneca Ab	Substituted quinazoline derivatives as inhibitors of aurora kinases
DE10204462A1 (de) *	2002-02-05	2003-08-07	Boehringer Ingelheim Pharma	Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
EP1480679B1 (en)	2002-02-26	2007-05-23	Astrazeneca AB	Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative
US7645878B2 (en)	2002-03-22	2010-01-12	Bayer Healthcare Llc	Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof
TWI324597B (en)	2002-03-28	2010-05-11	Astrazeneca Ab	Quinazoline derivatives
US20040044014A1 (en)	2002-04-19	2004-03-04	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
DE10217689A1 (de) *	2002-04-19	2003-11-13	Boehringer Ingelheim Pharma	Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, ihre Verwendung und Verfahren zu ihrer Herstellung
US20030225079A1 (en)	2002-05-11	2003-12-04	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy
DE10221018A1 (de) *	2002-05-11	2003-11-27	Boehringer Ingelheim Pharma	Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
US20040048887A1 (en)	2002-07-09	2004-03-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors
PA8578001A1 (es)	2002-08-07	2004-05-07	Warner Lambert Co	Combinaciones terapeuticas de inhibidores de quinasa de erb b y terapias antineoplasicas
CA2514479A1 (en)	2003-01-23	2004-08-05	T.K. Signal Ltd.	Irreversible inhibitors of egf receptor tyrosine kinases and uses thereof
PE20040945A1 (es) *	2003-02-05	2004-12-14	Warner Lambert Co	Preparacion de quinazolinas substituidas
US7223749B2 (en)	2003-02-20	2007-05-29	Boehringer Ingelheim International Gmbh	Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
CA2521348A1 (en)	2003-04-09	2004-10-21	Pfizer Products Inc.	Processes for the preparation of n-((((pyridinyloxy)-phenylamino) quinazolinyl)-allyl) acetamide derivatives and related compounds as well as intermediates of such processes and processes for the preparation of such intermediates
RU2005135337A (ru)	2003-04-16	2006-06-10	Астразенека Аб (Se)	Производные хиназолина для лечения злокачественного новообразования
MXPA06001989A (es)	2003-08-18	2006-05-17	Pfizer Prod Inc	Programa de dosificacion para un nuevo agente anticanceroso.
WO2005040125A1 (en)	2003-10-06	2005-05-06	Gpc Biotech Ag	Quinazoline derivatives for the treatment of herpesviral infections
CA2547284A1 (en)	2003-11-28	2005-06-09	Mitsubishi Pharma Corporation	Quinazoline derivative and process for producing the same
WO2005107758A1 (en) *	2004-05-06	2005-11-17	Warner-Lambert Company Llc	4-phenylamino-quinazolin-6-yl-amides

2005
- 2005-04-25 WO PCT/IB2005/001139 patent/WO2005107758A1/en not_active Ceased
- 2005-04-25 UA UAA200611675A patent/UA85706C2/ru unknown
- 2005-04-25 EA EA200601849A patent/EA011237B1/ru active Protection Beyond IP Right Term
- 2005-04-25 SI SI200531429T patent/SI1746999T1/sl unknown
- 2005-04-25 AT AT05732761T patent/ATE533490T1/de active
- 2005-04-25 KR KR1020087022983A patent/KR20080095915A/ko not_active Withdrawn
- 2005-04-25 AP AP2006003810A patent/AP2204A/xx active
- 2005-04-25 AU AU2005239878A patent/AU2005239878B9/en not_active Expired
- 2005-04-25 DK DK05732761.1T patent/DK1746999T3/da active
- 2005-04-25 PL PL05732761T patent/PL1746999T3/pl unknown
- 2005-04-25 EP EP05732761A patent/EP1746999B1/en not_active Expired - Lifetime
- 2005-04-25 ME MEP-2012-2A patent/ME01267B/me unknown
- 2005-04-25 MX MXPA06012756A patent/MXPA06012756A/es active IP Right Grant
- 2005-04-25 GE GEAP20059692A patent/GEP20084551B/en unknown
- 2005-04-25 ES ES05732761T patent/ES2374553T3/es not_active Expired - Lifetime
- 2005-04-25 HR HR20110958T patent/HRP20110958T1/hr unknown
- 2005-04-25 CN CN2005800145175A patent/CN1972688B/zh not_active Expired - Lifetime
- 2005-04-25 RS RS20120004A patent/RS52119B/sr unknown
- 2005-04-25 BR BRPI0510604A patent/BRPI0510604B8/pt active IP Right Grant
- 2005-04-25 CA CA2565812A patent/CA2565812C/en not_active Expired - Lifetime
- 2005-04-25 JP JP2007512544A patent/JP4205757B2/ja not_active Expired - Lifetime
- 2005-04-25 KR KR1020067023121A patent/KR100885835B1/ko not_active Expired - Lifetime
- 2005-04-25 PT PT05732761T patent/PT1746999E/pt unknown
- 2005-04-25 NZ NZ550796A patent/NZ550796A/en not_active IP Right Cessation
- 2005-04-29 MY MYPI20051908A patent/MY143566A/en unknown
- 2005-05-03 PE PE2005000494A patent/PE20060215A1/es active IP Right Grant
- 2005-05-03 TW TW094114254A patent/TWI334865B/zh active
- 2005-05-04 GT GT200500103A patent/GT200500103A/es unknown
- 2005-05-04 AR ARP050101797A patent/AR048652A1/es active IP Right Grant
- 2005-05-04 HN HN2005000192A patent/HN2005000192A/es unknown
- 2005-05-04 PA PA20058631901A patent/PA8631901A1/es unknown
- 2005-05-04 NL NL1028967A patent/NL1028967C2/nl not_active IP Right Cessation
- 2005-05-05 UY UY28885A patent/UY28885A1/es active IP Right Grant
- 2005-05-05 US US11/122,345 patent/US7772243B2/en active Active
2006
- 2006-10-23 IL IL178822A patent/IL178822A/en active IP Right Grant
- 2006-10-30 ZA ZA200609012A patent/ZA200609012B/xx unknown
- 2006-11-02 NI NI200600262A patent/NI200600262A/es unknown
- 2006-11-03 TN TNP2006000360A patent/TNSN06360A1/fr unknown
- 2006-11-03 CR CR8727A patent/CR8727A/es unknown
- 2006-11-03 MA MA29435A patent/MA28632B1/fr unknown
- 2006-11-08 EC EC2006006976A patent/ECSP066976A/es unknown
- 2006-12-06 NO NO20065626A patent/NO339692B1/no active Protection Beyond IP Right Term
2008
- 2008-07-11 JP JP2008180894A patent/JP4966923B2/ja not_active Expired - Lifetime
2010
- 2010-04-05 US US12/754,556 patent/US8466165B2/en active Active
2011
- 2011-12-02 CY CY20111101196T patent/CY1112127T1/el unknown
2013
- 2013-06-10 US US13/914,410 patent/US8623883B2/en not_active Expired - Lifetime
2019
- 2019-08-29 CY CY2019034C patent/CY2019034I2/el unknown
- 2019-09-05 NL NL301004C patent/NL301004I2/nl unknown
- 2019-09-10 LT LTPA2019016C patent/LTC1746999I2/lt unknown
- 2019-09-11 HU HUS1900039C patent/HUS1900039I1/hu unknown
- 2019-09-12 LU LU00127C patent/LUC00127I2/fr unknown
- 2019-09-12 BE BE2019C540C patent/BE2019C540I2/nl unknown
- 2019-09-12 FR FR19C1052C patent/FR19C1052I2/fr active Active
- 2019-09-13 NO NO2019035C patent/NO2019035I1/no unknown

Also Published As

Publication number	Publication date
LTC1746999I2 (lt)	2020-05-11
IL178822A0 (en)	2007-03-08
US8623883B2 (en)	2014-01-07
NO2019035I1 (no)	2019-09-13
CY2019034I1 (el)	2019-11-27
KR20070008683A (ko)	2007-01-17
NO339692B1 (no)	2017-01-23
HN2005000192A (es)	2010-06-09
CY1112127T1 (el)	2015-11-04
UA85706C2 (xx)	2009-02-25
AP2006003810A0 (en)	2006-12-31
US7772243B2 (en)	2010-08-10
BE2019C540I2 (nl)	2024-08-08
HK1106432A1 (en)	2008-03-14
TW200540163A (en)	2005-12-16
ECSP066976A (es)	2006-12-29
TNSN06360A1 (fr)	2008-02-22
JP2009007363A (ja)	2009-01-15
HRP20110958T1 (hr)	2012-01-31
BRPI0510604A (pt)	2007-10-30
WO2005107758A1 (en)	2005-11-17
LUC00127I2 (fr)	2020-10-06
TWI334865B (en)	2010-12-21
PT1746999E (pt)	2012-01-11
EP1746999B1 (en)	2011-11-16
EP1746999A1 (en)	2007-01-31
US20050250761A1 (en)	2005-11-10
FR19C1052I1 (nl)	2019-10-11
CY2019034I2 (el)	2019-11-27
KR20080095915A (ko)	2008-10-29
CA2565812A1 (en)	2005-11-17
GT200500103A (es)	2006-01-10
PE20060215A1 (es)	2006-03-20
LUC00127I1 (fr)	2019-09-19
NL1028967C2 (nl)	2006-06-27
MY143566A (en)	2011-05-31
JP4205757B2 (ja)	2009-01-07
NO20065626L (no)	2007-01-23
DK1746999T3 (da)	2012-01-23
NL1028967A1 (nl)	2005-11-08
CR8727A (es)	2006-11-30
NI200600262A (es)	2008-03-07
US20130274275A1 (en)	2013-10-17
FR19C1052I2 (fr)	2020-09-04
AP2204A (en)	2011-02-07
MA28632B1 (fr)	2007-06-01
PL1746999T3 (pl)	2012-07-31
HUS1900039I1 (hu)	2019-10-28
KR100885835B1 (ko)	2009-02-26
BRPI0510604B8 (pt)	2021-05-25
CA2565812C (en)	2012-03-13
BRPI0510604B1 (pt)	2020-05-12
US8466165B2 (en)	2013-06-18
ATE533490T1 (de)	2011-12-15
AR048652A1 (es)	2006-05-10
AU2005239878B9 (en)	2010-01-07
LTPA2019016I1 (lt)	2019-09-25
JP4966923B2 (ja)	2012-07-04
ES2374553T3 (es)	2012-02-17
US20100190977A1 (en)	2010-07-29
IL178822A (en)	2013-07-31
PA8631901A1 (es)	2005-11-25
ZA200609012B (en)	2008-06-25
UY28885A1 (es)	2005-12-30
EA011237B1 (ru)	2009-02-27
RS52119B (sr)	2012-08-31
CN1972688A (zh)	2007-05-30
NZ550796A (en)	2010-07-30
CN1972688B (zh)	2012-06-27
EA200601849A1 (ru)	2007-04-27
SI1746999T1 (sl)	2012-01-31
ME01267B (me)	2013-06-20
AU2005239878B2 (en)	2009-09-03
JP2007536368A (ja)	2007-12-13
MXPA06012756A (es)	2007-01-16
AU2005239878A1 (en)	2005-11-17
GEP20084551B (en)	2008-11-25

Publication	Publication Date	Title
NL301261I2 (nl)	2024-03-25	Gefapixant, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout.
NL301150I2 (nl)	2022-11-24	setmelanotide, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301042I1 (nl)	2020-06-17	Trifaroteen, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301004I2 (nl)	2026-01-21	Dacomitinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301049I1 (nl)	2020-07-01	Crisaborale, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301299I2 (nl)	2024-12-11	Capivasertib, eventueel in de vorm van een farmaceutisch aanvaardbaar zout
NL300863I2 (nl)	2017-08-03	Palbociclib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL300974I2 (nl)	2022-04-06	Binimetinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout of solvaat
NL301067I2 (nl)	2020-10-28	Cefiderocol, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout of solvaat
NL301021I1 (nl)	2019-12-18	talazoparib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout.
NL301106I2 (nl)	2021-08-03	Cenobamaat of een farmaceutisch aanvaardbaar zout daarvan
NL301020I2 (nl)	2020-04-21	Avatrombopag, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder avatrombopag-maleaat
NL301199I2 (nl)	2023-02-16	Difelikefalin, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, hydraat, solvaat, zuurzout-hydraat of N-oxide
NL300946I2 (nl)	2018-09-26	Brexpiprazole, desgewenst in de vorm van een zout
NL300913I2 (nl)	2017-12-20	Cariprazine, optioneel in de vorm van een zout, waaronder cariprazine hydrochloride
NL301256I2 (nl)	2024-01-11	cedazuridine, of een farmaceutisch aanvaardbaar zout daarvan
NL301057I2 (nl)	2020-09-10	Glasdegib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, met inbegrip van het maleaatzout
NL301321I2 (nl)	2025-07-17	Delgocitinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout of solvaat daarvan
NL301037I2 (nl)	2020-05-12	Solriamfetol of een farmaceutisch aanvaardbaar zout daarvan, bij voorkeur het hydrochloridezout daarvan
NL301209I2 (nl)	2023-01-24	capmatinib of een farmaceutisch aanvaardbaar zout daarvan
NL300909I2 (nl)	2017-12-19	Ribociclib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301202I2 (nl)	2023-01-24	Linzagolix, of een farmaceutisch aanvaardbaar zout daarvan, zoals linzagolix choline
NL300971I2 (nl)	2019-04-11	Eravacycline, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
FIC20253002I1 (fi)	2025-05-23	Otsanimodi, tai sen farmaseuttisesti hyväksyttävä suola, mukaan lukien hydrokloridisuola
NL301033I2 (nl)	2020-04-15	Larotrectinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, in het bijzonder larotrectinibsulfaat, met inbegrip van larotrectinibsulfaat monohydraat